首页 | 本学科首页   官方微博 | 高级检索  
     


Chemo-endocrine therapy in patients with stage D2 prostate cancer
Authors:Yoko Kubota  Teruhiro Nakada  Kyoichi Imai  Hidetoshi Yamanaka  Hideki Sakai  Yutaka Saito  Yukio Tomaru  Koichi Kitamura  Osamu Sugano  Isoji Sasagawa
Abstract:There have only been a few studies of chemo-endocrine therapy compared with endocrine therapy alone in newly diagnosed prostate cancer patients. We assessed the effects of these two therapies by comparing long-term survival rates. One hundred and twenty-nine patients were entered in this study between November 1977 and March 1992. Seventy-seven patients were treated with endocrine therapy alone. Other 52 patients received chemo-endocrine therapy, which included orchiectomy and/or diethylstilbestrol diphosphate (DES-DP) plus Cisplatin, with or without other cytotoxic agents. All patients had bone metastasis at the beginning of the study. There was a significant difference in survival between patients who received endocrine therapy and chemo-endocrine therapy (P = 0.0078). That is, survival rate was superior for the chemoendocrine therapy patients throughout the entire follow-up period. These data suggest that early chemo-endocrine therapy containing Cisplatin, with or without maintenance chemotherapy, is a potentially effective treatment for newly diagnosed metastatic prostate cancer and is worth further investigation via a randomized trial.
Keywords:prostate cancer  Cisplatin  Adriamycin
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号